September 02, 2025 21:33 ET | Source: Mineralys Therapeutics, Inc. RADNOR, Pa., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics,…
New investors NEA and SR One lead round alongside existing investors OrbiMed, F-Prime, NVIDIA and Khosla VenturesCHARM’s AI-designed menin inhibitor…
All dollar amounts reflected in Canadian dollars unless otherwise stated August 28, 2025 18:12 ET | Source: Rakovina Therapeutics Inc…
August 27, 2025 20:53 ET | Source: Cognition Therapeutics, Inc. - The offering was made to two new fundamental institutional…
Vivoryon Therapeutics N.V. to Report H1 2025 Financial Results and Operational Progress on September 4, 2025 Halle (Saale) / Munich,…
- Successfully initiated enrollment in advanced Phase 2 ovarian cancer trial - Expanded global IP protection by securing…
August 15, 2025 07:30 ET | Source: Plus Therapeutics Inc. HOUSTON, Aug. 15, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc.…
TORONTO, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R),…
First patient in Phase I/II clinical trial expected to be enrolled in Q4 2025UK Clinical Trial Application (CTA) approval shortly…
August 01, 2025 16:08 ET | Source: Protara Therapeutics NEW YORK, Aug. 01, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc.…